Board summary
Key figures
30,151
Registered population
57.1% aged 18–64
25.5%
Aged 65+
ICB 19.0% · England 17.9%
2.5%
Ethnic minority (non-White)
0.9% Asian · England 9.6%
9.5%
In IMD quintile 1
ICB 31.9% · England 21.0%
~3,701
Core20 residents (est.)
Resident basis; registered basis ~3,784 · see page 3
6,373
Hypertension register
+7.18% in 3 yrs · England +5.60%
272
SMI register
12% of St. Helens (LAD)'s
701
COPD register
Reviews +5.02% in 3 yrs
Forecast to 2030
7,601
Hypertension patients, 2030
+1,228 on today
71.6%
QRISK ≥20% on statins, 2030
+5.22pp over 3 yrs
6.3%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
SMI physical health checks fell over three years.
Over 2023 to 2025, psychosis alcohol recording fell 11.0 pp to 76.5% (England +5.4 pp), alongside BMI (-8.1 pp) and BP (-7.4 pp).
High-risk lipid therapy trails national and local benchmarks.
Patients with QRISK ≥ 20% on lipid-lowering therapy reached 59.6% (England 63.6%), alongside 8,640 lipid items per 1,000 aged 65+ (England 18,056 rate).
Hypertension blood pressure control exceeds all comparators.
Hypertension patients treated to target reached 75.3% against 69.3% in St. Helens (LAD) and 70.3% in England, rising +8.3% over 2023 to 2025.
Population, age and ethnicity
Registered patients aged 65+ reach 25.5%, exceeding England by 7.6 percentage points
Across 30,151 registered patients, 25.5% (7,691) are aged 65+, above St. Helens (LAD) (20.1%), NHS Cheshire and Merseyside Integrated Care Board (19.0%), and England (17.9%). Adults aged 18–64 comprise 57.1% (LAD 61.1%, ICB 61.9%, England 62.7%) and children aged 0–17 represent 17.4% (LAD 18.7%, ICB 19.2%, England 19.6%). Projected list growth to 2030 is 2.4% (unverified methodology). Census usual residents in associated areas are 97.5% White (LAD 96.5%, ICB 93.0%, England 81.1%), leaving a 2.5% ethnic minority share.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are St. Helens (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (St. Helens LA) | 2,208 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 86.8% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 59.5% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (St. Helens LA) | 1,143 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (St. Helens LA) | 24.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 9.5% overall but concentrated entirely within two practices
The PCN Core20 cohort is 9.5%, below St. Helens (LAD) (38.5%), NHS Cheshire and Merseyside Integrated Care Board (31.9%), and England (21.0%), with an average IMD decile of 6.1. A 3.03 percentage point reconciliation difference exists between the PCN rate and the 12.5% weighted practice share. Core20 workload is concentrated at Windermere Medical Centre (57.7%, 2,256 estimated patients) and Bethany Medical Centre (35.9%, 1,528 estimated patients), while four practices record 0.0%. Targeted outreach and Core20 resources can focus on these two practices where identified workload resides.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
272
SMI register
0.92% recorded prevalence
138
Learning disability register
0.47% recorded prevalence
13
Care homes, 334 beds
In the PCN catchment
11.7%
Provide unpaid care
St. Helens (LAD), Census 2021
Recorded learning disability prevalence is 0.5% (138 patients; St. Helens (LAD) 0.6%, NHS Cheshire and Merseyside ICB 0.6%, England 0.6%) and severe mental illness is 0.9% (272 patients; LAD 1.1%, ICB 1.1%, England 1.0%). The catchment includes 13 care homes with 334 beds.
Severe mental illness: physical health checks
Over 2023 to 2025, recorded SMI checks fell 11.0 pp for alcohol (England +5.4 pp), 8.1 pp for BMI (England +5.1 pp), and 7.4 pp for blood pressure (England +4.4 pp), which could reflect worsening recall or coding.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,373
Hypertension register
+7.18%
Register growth, 3 yrs
St. Helens (LAD) +5.27% · England +5.60%
+4.68pp
BP control, under 80
≤140/90 · +2.66pp aged 80+
+1,228
More patients by 2030
Forecast 7,601 (24.68%)
Hypertension case-finding and control
Hypertension QOF prevalence is 21.5% (6,373 patients), above England (15.2%), St. Helens (LAD) (18.7%), and NHS Cheshire and Merseyside Integrated Care Board (16.8%). Over 2023 to 2025, prevalence grew +1.4 pp (+7.2%, England +0.8 pp). Blood pressure control is strong: 75.3% are treated to target (England 70.3%), and 71.7% aged under 80 achieve <= 140/90 mmHg (England 67.8%). Across practices, recorded prevalence spans from 14.7% at Windermere Medical Centre to 25.9% at Rainford Health Centre. Crude prevalence does not establish undiagnosed disease, and the implied base (29,669) differs from the 30,151 list. Blood pressure control exceeds England, but recorded prevalence varies across practices, suggesting case-finding should be prioritized where prevalence is lowest.
Lipids and statins
Lipid-lowering therapy for QRISK ≥ 20% reaches 59.6%, trailing England (63.6%), St. Helens (LAD) (62.1%), and NHS Cheshire and Merseyside Integrated Care Board (63.2%). In patients aged 65+, lipid prescribing is 8,640 per 1,000 (England 18,056 rate). Fewer at-risk patients receive lipid-lowering therapy than England implies, prioritizing primary prevention recall audits.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 66,447 | £1.60 | £1.71 | £1.86 | £106,315 |
| Cardiovascular (all), 2025 | 101,829 | £4.15 | £4.37 | £3.33 | £422,590 |
In 2026, 66,447 items of lipid-modifying drugs were prescribed at £1.60 per item, below England (£1.86), St. Helens (LAD) (£1.75), and NHS Cheshire and Merseyside Integrated Care Board (£1.71). PCN spend was £17,276 less than at England's unit cost. Spending less per item than England offers headroom to expand lipid therapy to under-treated cohorts.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+1.61%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+3.51%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 8.9% (2,526 patients), above England (6.6%), St. Helens (LAD) (8.2%), and the ICB (7.0%). Prescribed asthma management items for ages 5–19 reached 2,691 per 1,000 (England 1,488 rate). Over 2023 to 2025, asthma reviews rose +1.6% to 68.5%, trailing England's +4.4% growth and leaving 796 unreviewed on the register scale. COPD prevalence is 2.4% (701 patients), above England (1.9%) but below the borough (2.9%), while COPD reviews reached 80.6% (England 76.4%). Slower review growth alongside high prescribing suggests proactive asthma review recall could be prioritised.
Cancer register and children's immunisation
The cancer register records 1,494 patients (5.0%, above England 3.8%). In Q1 2025/26, age-5 MMR1 reached 98.3%, exceeding the 95.0% target. However, age-5 MMR2 was 91.5% (a 6.8 pp difference), the 4-in-1 booster was 86.4% (8.6 pp below target), and 24-month MMR1 reached 87.9% (7.1 pp below target). Slower pre-school booster completion indicates second-dose and booster follow-up could be prioritised.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
At ICB level (wider system data, not PCN performance), in 2022, 55.5% of staged cancers across NHS Cheshire and Merseyside ICB were diagnosed at stage 1 or 2 (7,482 of 13,490 known-stage cases; England 55.3%), below the 75.0% national ambition by 19.5 pp. Known stage was recorded for 72.8% of cases (13,490 of 18,522 registered cancers; England 67.0%), requiring about 2,640 additional early-stage diagnoses annually across the ICB to reach the ambition. Across ST HELENS NORTH PCN, cancer prevalence is 5.0% (1,494 patients). While PCN cervical screening reaches 76.3% (England 66.8%), coverage is 67.1% at Windermere Medical Centre.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At provider level (wider system data, not PCN performance), in provisional July 2026 data, Mersey and West Lancashire Teaching Hospitals NHS Trust met the 62-day cancer standard for 78.0% of pathways (England 71.2%, ICB 76.2%), below the 85.0% standard by 7.0 pp. The trust achieved 72.4% on the 28-day faster diagnosis standard (standard 75.0%), behind Liverpool University Hospitals NHS Foundation Trust (75.5%) and Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust (82.8%). In diagnostics, 23.3% of patients waited 6+ weeks for non-obstetric ultrasound (England 19.6%), and 14.0% for MRI.
| Pathways within standard (%) | Mersey and West Lancashire | Wrightington, Wigan and Leigh | Liverpool | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 72.39 | 82.80 | 75.47 | 77.25 | 79.32 |
| 31-day treatment (96%) | 95.46 | 89.04 | 90.51 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 77.96 | 76.78 | 73.26 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Mersey and West Lancashire | Wrightington, Wigan and Leigh | Liverpool | England |
|---|---|---|---|---|
| MRI | 14.04 | 0.49 | 6.42 | 21.40 |
| CT | 13.08 | 7.78 | 0.71 | 9.92 |
| Echocardiography | 34.88 | 24.37 | 12.55 | 28.48 |
| Colonoscopy | 18.04 | 6.10 | 33.14 | 30.83 |
| Gastroscopy | 18.17 | 12.54 | 44.99 | 29.02 |
| All 15 DM01 tests | 21.17 | 14.36 | 11.50 | 23.14 |
| Community services activity | St. Helens residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 48,525 | 541,280 |
| Referrals | 7,815 | 97,150 |
| Patients with a contact | 12,745 | 146,240 |
Community services (residents of St. Helens), Jun 2026 (provisional). At borough level (wider system data, not PCN performance), in provisional June 2026 data from the Community Services Dataset, 59.9% of community contacts for St. Helens borough residents were with adults aged 65 and over (29,090 of 48,525 contacts). With 25.5% of PCN registered patients aged 65+, intermediate care and district nursing provide key infrastructure for post-diagnostic monitoring and local palliative support.
Practice variation and patient experience
Vaccination achievement varies by 66.5 pp across captured practices
Across captured practices, the range in QOF vaccination and immunisation-domain achievement is 66.5 pp. In 2025/26, Windermere Medical Centre recorded 23.9% (England 55.2%), while Bethany Medical Centre reached 90.4%. In overall QOF achievement for 2025/26, Windermere Medical Centre achieved 91.4% and Bethany Medical Centre achieved 97.1% (England 92.5%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Kenneth Macrae | 114 | 0.0 | 92.4% | 66.3% | 97.7% |
| Rainford | 100 | 0.0 | 89.6% | 73.5% | 96.9% |
| Windermere | 107 | 57.7 | 83.3% | 83.6% | 93.0% |
| Billinge Medical | 123 | 0.0 | 78.3% | 79.6% | 92.8% |
| Bethany | 108 | 35.9 | 85.2% | 78.4% | 86.5% |
| Garswood Surgery | 114 | 0.0 | 84.5% | 69.6% | 78.4% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Three-year SMI alcohol recording fell 11.0 pp while heart failure reviews rose +16.0%
Over 2023 to 2025, physical health checks for the 272 patients on the severe mental illness register fell, trailing England: alcohol recording fell 11.0 pp (England +5.4 pp), BMI recording fell 8.1 pp (England +5.1 pp), and blood pressure checks fell 7.4 pp (England +4.4 pp). Asthma review growth (+1.6%) trailed England (+4.4%). Conversely, heart failure reviews rose +16.0% (England +8.7%) and hypertension treated to target rose +8.3% (England +3.6%). This mental health check lag could reflect recall or coding issues, which an audit could test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Alcohol record (psychosis)
BMI record (SMI)
BP check (SMI)
Asthma reviews
Stroke register
Heart failure reviews
Hypertension treated to target
BP control, under 80
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | St. Helens (LAD) | Asset | PCN | St. Helens (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 13 (334 beds) | n/a | Schools (catchment) | 43 | n/a |
| Children's centres | 1 | 8 | Places of worship | 39 | 90 |
| Libraries | 4 | 15 | Primary schools (LA maintained) | 15 | 32 |
| Primary academies | 3 | 11 | Special schools | 1 | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
SMI physical health check recall
Over 2023 to 2025 across the 272-patient SMI register, alcohol recording fell 11.0 pp to 76.5% (England +5.4 pp), BMI fell 8.1 pp to 76.5% (England +5.1 pp), and BP fell 7.4 pp to 83.2% (England +4.4 pp). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 2
Pre-school booster and MMR2 recall
In Q1 2025/26 (cohort 59), age-5 MMR1 is 98.3%, while MMR2 is 91.5% (6.8 pp difference; 3.5 pp below the 95.0% target) and the 4-in-1 booster is 86.4% (8.6 pp below target). For discussion: run targeted pre-school recall for children missing MMR2 or the 4-in-1 booster, offering flexible clinic slots. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
Structured asthma review recall
Asthma prevalence is 8.9% (2,526 patients; England 6.6%), while 2023 to 2025 review growth (+1.6% to 68.5%) trailed England (+4.4%), leaving 796 patients (about 800) unreviewed on the register scale. For discussion: run a single-template asthma recall prioritising repeat inhaler prescriptions, offering after-school slots for children. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Targeted Core20 practice outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check audit (p4) | Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Targeted hypertension case finding (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · SMI physical health check recall (p12) | Severe mental illness register · Patients with psychosis who have a current record of alcohol consumption · Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Option 2 · Pre-school booster and MMR2 recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 3 · Structured asthma review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
